2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease

关于 BACE 蛋白酶在健康和疾病中的作用的第二届 Kloster Seeon 会议

• 批准号: 9195559
• 负责人: ROBERT J VASSAR
• 金额: $ 3.4万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-07-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9195559
• 关键词: Academia; Advanced Development; Adverse effects; Air; Alzheimer disease prevention; Alzheimer' s Disease; Amyloid beta-Protein; Amyloid beta-Protein Precursor; Animal Model; Area; Aspartic Endopeptidases; Award; Behavior; Biochemical; Biological; Brain; Case Study; Cells; Cerebrum; Cleaved cell; Clinical; Clinical Trials; Communities; Complex; Development; Disease; Disease Progression; Enzymes; Fostering; Funding; Genetic; Germany; Goals; Health; Human; Industry; International; Internet; Journals; Knockout Mice; Knowledge; Laboratories; Location; Mutation; Nervous System Physiology; Neurites; Neurosciences; Paper; Pathogenesis; Peptide Hydrolases; Pharmaceutical Preparations; Physiological; Postdoctoral Fellow; Process; Production; Publications; Publishing; Reading; Regulation; Reporter; Reporting; Research; Research Personnel; Retinal; Risk; Role; Safety; Science; Scientist; Senile Plaques; Senior Scientist; Site; Staging; Students; Therapeutic; Toxic effect; Training; Travel; United States National Institutes of Health; Universities; Writing; abeta accumulation; abstracting; amyloid peptide; base; beta secretase; beta-site APP cleaving enzyme 1; cost; drug development; experience; graduate student; improved; inhibitor/antagonist; lectures; meetings; novel; peptide A; posters; prevent; professional atmosphere; programs; research and development; secretase; success; symposium; therapeutic target; transmission process; web site

Project Summary Compelling genetic, biochemical, cell biological, animal model, and human studies suggest that cerebral accumulation of the -amyloid peptide (A) has a critical early role in Alzheimer's disease (AD) pathogenesis. The -secretase enzyme BACE1 is the rate-limiting enzyme for A production. Thus, BACE1 is a prime therapeutic target for the treatment or prevention of AD. Several BACE1 inhibitor drugs for AD are in clinical trials, but the safety and efficacy of these agents are unknown. The BACE proteases field comprises very active and diverse areas of research that have high impact on therapeutic approaches to treat and prevent AD. Here, I propose the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease, September 25-27, 2016, in Bavaria, Germany, which has the following objectives: 1) disseminate the latest information on BACE proteases research and catalyze discussion among scientists in academia and industry, 2) promote the training of young scientists, and 3) publish a state-of-the-art review of BACE research to help advance the field and facilitate the development of safe and effective BACE inhibitor drugs for AD. The Scientific Program consists of: 1) a Keynote Lecture by Dr. Kari Stefansson (DeCode Genetics), who recently discovered a mutation in APP that protects against AD by reducing BACE1 cleavage, thus providing proof of concept for therapeutic BACE1 inhibition, 2) two full days of sessions comprising 25-minute talks from 24 leading experts in the BACE proteases field, 3) a session of 2-minute flash talks given by 10 selected graduate students and post-doctoral researchers to introduce their posters, 4) poster sessions on each of two evenings that will enhance the training experience of students and post-docs, 5) a panel discussion between academic and industry scientists on the current state of BACE research and drug development, 6) a conclusion and summary session to remark on the meeting and discuss the direction forward for the field. This meeting is co-organized by Drs. Stefan Lichtenthaler (Technical University Munich) and Robert Vassar (Northwestern University), two leading scientists in the BACE proteases field. The 1st Kloster Seeon Meeting on BACE Proteases in Health and Disease was held at the same location on October 6-8, 2013, and was objectively successful at disseminating the latest BACE research and catalyzing discussion among BACE scientists. Three years have passed, and significant advances in BACE research have been made, including new clinical trials, discoveries of novel BACE1 substrates and functions, different mechanisms of BACE regulation in health and dysregulation in AD, and identification of new proteolytic activities. Given these new advances, the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease is timely and important for dissemination of the latest information in the field. Additionally, no other scientific meeting or conference focuses exclusively on BACE proteases research, making this meeting a unique scientific forum that will contribute significantly to the advancement of the AD research and drug development fields.

项目摘要 令人信服的遗传学、生物化学、细胞生物学、动物模型和人类研究表明， β-淀粉样肽（A β）的积累在阿尔茨海默病（AD）发病机制中具有关键的早期作用。 β-分泌酶BACE 1是A β产生的限速酶。因此，BACE 1是一个素数 本发明提供了用于治疗或预防AD的治疗靶点。几种治疗AD的BACE 1抑制剂药物已进入临床 试验，但这些药物的安全性和有效性是未知的。BACE蛋白酶领域包括非常 活跃和多样化的研究领域，对治疗和预防AD的治疗方法有很大影响。 在这里，我提议在9月25日至27日举行的第二届Kloster Seeon会议上讨论BACE蛋白酶在健康和疾病中的作用， 2016年，在巴伐利亚州，德国，它有以下目标：1）传播BACE的最新信息 蛋白酶研究和催化学术界和工业界科学家之间的讨论，2）促进 培训年轻科学家，3）出版BACE研究的最新评论，以帮助推进该领域的发展 有利于开发安全有效的AD BACE抑制剂药物。科学计划 包括：1）Kari Stefansson博士（解码遗传学）的主题演讲，他最近发现了一种 APP中的突变，通过减少BACE 1切割来保护AD，从而为以下概念提供了证据： 治疗性BACE 1抑制，2）为期两天的会议，包括24位领先专家的25分钟演讲 在BACE蛋白酶领域，3）由10名选定的研究生进行2分钟的快速演讲， 博士后研究人员介绍他们的海报，4）海报会议在两个晚上，将 加强学生和博士后的培训经验，5）学术和 行业科学家对BACE研究和药物开发的现状，6）结论和总结 会议期间，与会者就会议发表意见，并讨论该领域的前进方向。本次会议由 Stefan Lichtenthaler博士（慕尼黑工业大学）和Robert Vassar博士（西北大学），两名 BACE蛋白酶领域的顶尖科学家。第一次Kloster Seeon会议关于BACE蛋白酶在健康中的作用 2013年10月6日至8日在同一地点举行，客观上取得了成功， 传播BACE的最新研究成果，促进BACE科学家之间的讨论。三年 通过，BACE研究取得了重大进展，包括新的临床试验，发现 新的BACE 1底物和功能，BACE调节在健康中的不同机制， AD中的失调，并鉴定新的蛋白水解活性。鉴于这些新的进展，第二克洛斯特 关于健康和疾病中BACE蛋白酶的Seeon会议对于传播 该领域的最新信息。此外，没有其他科学会议或会议专门关注 BACE蛋白酶研究，使本次会议成为一个独特的科学论坛，将大大有助于 AD研究和药物开发领域的进步。